Clinical Trial Update: An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial update of PB101, an autologous NK/CIK cell product, in combination with an EGFR-TKI, for non-small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR-TKI (EGFR tyrosine kinase inhibitor)
• PB101 (autologous NK/CIK cell product)

Snippet

Sponsor: Precision Biotech Taiwan Corp. | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED